Biocryst Pharmaceuticals (BCRX) Free Cash Flow Growth (1y) (2011 - 2026)
Biocryst Pharmaceuticals (BCRX) Free Cash Flow Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 10.34% |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | -13.65% |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | 56.40% |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | -5.85% |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | -29.32% |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 166.91% |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | 44.93% |
| 10 | Biocryst Pharmaceuticals | 2.35 Bn | 2.28 Bn | 151.04 Mn | -126.77% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -126.77% |
| Dec 31, 2025 | 6,250.67% |
| Sep 30, 2025 | 426.26% |
| Jun 30, 2025 | 3,651.02% |
| Mar 31, 2025 | 48.97% |
| Dec 31, 2024 | 34.78% |
| Sep 30, 2024 | 137.33% |
| Jun 30, 2024 | 94.12% |
| Mar 31, 2024 | -13.10% |
| Dec 31, 2023 | 70.03% |
| Sep 30, 2023 | 35.98% |
| Jun 30, 2023 | 31.14% |
| Mar 31, 2023 | 39.04% |
| Dec 31, 2022 | 27.38% |
| Sep 30, 2022 | -37.98% |
| Jun 30, 2022 | -6.78% |
| Mar 31, 2022 | -27.98% |
| Dec 31, 2021 | 21.36% |
| Sep 30, 2021 | 38.48% |
| Jun 30, 2021 | 15.71% |